US 5579250A
· Balaji et al.
· 1996
[cited by applicant]
US 5612895A
· Balaji et al.
· 1997
[cited by applicant]
US 5631280A
· Ciccarone et al.
· 1997
[cited by applicant]
CA 3081414A1
· 2019
[cited by applicant]
EP 3704262A1
· 2020
[cited by applicant]
JP 2021500925A
· 2021
[cited by applicant]
WO 2015089419A2
· 2015
[cited by applicant]
WO 2016024281A1
· 2016
[cited by applicant]
WO 2019089561A1
· 2019
[cited by applicant]
Akinc et al., “Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms,” Mol. Ther., 18(7):1357¬1364 (2010).
[cited by applicant]
Alabi et al., “Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery,” Proc. Natl. Acad. Sci. U S A., 110(32):12881-6 (2013).
[cited by applicant]
Bertrand et al., “Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics,” Nat. Commun., 8(1):777 (2017).
[cited by applicant]
Chahal et al., “Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose,” Proc. Natl. Acad. Sci. U S A., 113(29):E4133-42 (2016).
[cited by applicant]
Chen et al., “Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation,” J. Am. Chem. Soc., 134:6948-6951 (2012).
[cited by applicant]
Coelho et al., “Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis,” N. Engl. J. Med., 369(9):819-829 (2013).
[cited by applicant]
Cory D. Sago et al: “High-throughput in vivo screen of functional Mrna delivery identifies nanoparticles for endothelial cell gene editing”, Proceedings of the National Academy of Sciences of the United States of Americ…
[cited by applicant]
Dahlman et al., “In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight,” Nat. Nanotechnol., 9(8):648-655 (2014).
[cited by applicant]
Davis, “Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin,” Adv. Drug. Deliv. Rev., 61(13):1189-92 (2009).
[cited by applicant]
Dong et al., “Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates,” Proc. Natl. Acad. Sci. U S A., 111(11):3955-60 (2014).
[cited by applicant]
Dong et al., “Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo,” Nano Lett., 16(2):842-8 (2016).
[cited by applicant]
Eltoukhy et al., “Nucleic acid-mediated intracellular protein delivery by lipid-like nanoparticles,” Biomaterials., 35(24):6454-6461 (2014).
[cited by applicant]
Gaudreault et al., “Increased caveolin-1 expression in Alzheimer's disease brain,” Neurobiology of Aging, 25(6):753-759 (2004).
[cited by applicant]
Gaur et al., “Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer,” Nanomedicine., 8(5):721-730 (2012).
[cited by applicant]
Green et al., “A Combinatorial Polymer Library Approach Yields Insight into Nonviral Gene Delivery,” Acc. Chem. Res., 41(6):749-759 (2008).
[cited by applicant]
Gvaramia et al., “Role of caveolin-1 in fibrotic diseases,” Matrix Biol., 32(6):307-315 (2013).
[cited by applicant]
Hao et al., “Rapid Synthesis of a Lipocationic Polyester Library via Ring-Opening Polymerization of Functional Valerolactones for Efficacious siRNA Delivery,” J. Am. Chem. Soc., 137(29):9206-9209 (2015).
[cited by applicant]
Hindson et al., “Absolute quantification by droplet digital PCRCR versus analog real-time PCRCR,” Nat. Methods, 10(10):1003-1005 (2013).
[cited by applicant]
International Preliminary Report on Patentability received for International Application PCT/US2018/058171, mailed on May 5, 2020. (9 pages).
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US18/058171, mailed on May 14, 2020, 10 pages.
[cited by applicant]
International Search Report and Written Opinion received for International Application PCT/US2018/058171, mailed on Jan. 1, 2019. (14 pages).
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US18/058171, mailed on Jan. 15, 2019, 13 pages.
[cited by applicant]
James E. Dahlman et al.: “Barcoded nanoparticles for high througput in vivo discovery of targeted therapeutics”, Proceedings of the National Academ of Sciences of the United States of America, vol. 114, No. 8, Feb. 6, 2…
[cited by applicant]
Kaczmarek et al., “Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs,” Angew Chem. Int. Ed. Engl., 55(44):13808-13812 (2016).
[cited by applicant]
Kathryn A. Whitehead et al: “Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity”, Nature Communications, vol. 5, Jun. 27, 2014.
[cited by applicant]
Ming Want et al: “Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles”, Proceedings of the National Academy of Sciences of the United States of America, vol. 113, No. 11, Feb. 29, 2016.
[cited by applicant]
Nair et al., “Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GaINAc-siRNA conjugates, ” Nucleic Acids Res., 45(19): 10969-10977 (2017).
[cited by applicant]
Paunescu et al., “Detecting and Number Counting of Single Engineered Nanoparticles by Digital Particle Polymerase Chain Reaction,” ACS nano., 9(10):9564-9572 (2015).
[cited by applicant]
Paunovska et al., “A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation,” Nano. Lett., 18(3):2148-2157 (2018).
[cited by applicant]
Porel et al., “Sequence-defined bioactive macrocycles via an acid-catalysed cascade reaction,” Nat. Chem., Jun.;8(6):590-596 (2016).
[cited by applicant]
Ronan et al., “Avoiding common pitfalls when clustering biological data,” Sci. Signal., 9(432):re6 (2016).
[cited by applicant]
Sager et al., “Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure,” Circ. Res., 119(7):853-864 (2016).
[cited by applicant]
Sager et al., “RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction,” Sci. Transl. Med., 8(342): 342ra80 (2016).
[cited by applicant]
Sahay et al., “Endocytosis of Nanomedicines,” J. Control Release., 145(3):182-195 (2010).
[cited by applicant]
Semple et al., “Rational design of cationic lipids for siRNA delivery,” Nat. Biotechnol., 28(2):172-176 (2010).
[cited by applicant]
Siegwart et al., “Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery,” Proc. Natl. Acad Sci. U S A., 108(32):12996-13001 (2011).
[cited by applicant]
Sorkin et al., “Versatile Platform for the Synthesis of Orthogonally Cleavable Heteromultifunctional Cross-Linkers,” Bioconjug. Chem., 28(4):907-912 (2017).
[cited by applicant]
Sotgia et al., “Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment,” Breast Cancer Res., 13(4):213 (2011).
[cited by applicant]
Tanowitz et al., “Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes,” Nucleic Acids Res., 45…
[cited by applicant]
Turnbull et al., “Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents,” Methods Mol. Biol., 1521:153-166 (2017).
[cited by applicant]
Witkiewicz et al., “An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers,” Am. J. Pathol., 174(6):2023-2034 (2009).
[cited by applicant]
Yan et al., “Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells,” Proc. Natl. Acad. Sci. U S A., 113(39):E5702-E5710 (2016).
[cited by applicant]
Yang et al., “Caveolin-1 Expression in Clinically Confined Human Prostate Cancer: A Novel Prognostic Marker1,” Cancer Res., 59(22):5719-5723 (1999).
[cited by applicant]
Yang, “Nucleases: Diversity of Structure, Function and Mechanism,” Quarterly reviews of biophysics, 44(1):1-93 (2011).
[cited by applicant]
Zamboni et al., “Polymeric Nanoparticles as Cancer-specific DNA Delivery Vectors to Human Hepatocellular Carcinoma,” J. Control Release, 263:18-28 (2017).
[cited by applicant]
Zhang et al., “Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo,” ACS Appl. Mater Interfaces, 9(30):25481-25487 (2017).
[cited by applicant]
Zhang et al., “Lipid-Modified Aminoglycoside Derivatives for in vivo siRNA Delivery,” Adv Mater, 25(33):4641-4645 (2013).
[cited by applicant]
Zhou et al., “Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model,” Proc. Natl. Acad. Sci. U S A., 113(3):520-525 (2016).
[cited by applicant]
Zimmermann et al., “Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate, ” Mol. Ther., Jan. 4;25(1):71-78 (2017).
[cited by applicant]
Zuckerman et al., “siRNA Delivery to the Glomerular Mesangium Using Polycationic Cyclodextrin Nanoparticles Containing siRNA,” Nucleic Acid Ther., 25(2):53-64 (2015).
[cited by applicant]